What Will Year 1 Look Like for Adalimumab Biosimilars?
Share
Subscribe
This summer, Vizient, a member-owned health care consulting company, published its Pharmacy Market Outlook report for 2022. The report provided insight into the current status of the US biosimilar market place and broke down some of the key aspects stakeholders should keep an eye on as the United States enters a new phase of biosimilar competition.
On this episode, The Center for Biosimilars® welcomes Steven Lucio, PharmD, BCPS, senior principal of pharmacy solutions at Vizient. Dr. Lucio has been working with Vizient on its Pharmacy Market Outlook report, which makes several predictions for how the biosimilar market is expected to develop in the near future, including how the first year of adalimumab.
This episode is part of a larger series called “WHEN CHOICES ARRIVE: Competition & Consequences,” consisting of 4 articles and 2 podcasts. The series delves into everything that stakeholders need to know as everyone prepares for the 2023 introduction of adalimumab biosimilars.
To read part 2 of this series, “For Patients and Employers, 2023 Means a Changed Landscape,” click here.
To read part 3 of this series, “How Adalimumab Biosimilars Will Impact Clinicians,” click here.
To listen to the other podcast in this series, “What Will Year 1 Look Like for Adalimumab Biosimilars?” click here.